share_log

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

モルガンスタンレーは2024年の setbacks にもかかわらず、ポジティブなメドテックの見通しを維持し、インテュイティブサージカルとストライカーを格上げし、ネブロとグラウコスを格下げしました。

Benzinga ·  12/03 03:29

Last year,Morgan Stanleyupgraded its outlook for the U.S. MedTech sector to "Attractive," believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.

However, this view didn't play out as expected, mainly due to unforeseen, company-specific issues, such asDexCom, Inc's(NASDAQ:DXCM) unexpected Q2 channel mix challenges,Edwards Lifesciences Corporation's(NYSE:EW) slowdown in TAVR procedures,TransMedics Group, Inc's(NASDAQ:TMDX) seasonal impacts, andiRhythm Technologies, Inc's(NASDAQ:IRTC) DOJ investigation.

Morgan Stanley is bullish on the MedTech industry as volumes and pipelines continue to be...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする